Fortrea Holdings FTRE
NASDAQ FTRE
$18.27 -0.35 (-1.85%)
As of: Sep 4, 2026 · 11:49 AM EDT

Fortrea Holdings (FTRE) Restructuring Costs (2022 - 2026)

Fortrea Holdings' (FTRE) quarterly Restructuring Costs came in at $7.6 million in Q4 2023, up 181.48% YoY from $2.7 million in Q4 2022, and down 34.48% on a QoQ basis from $11.6 million in Q3 2023.

Analysis

Fortrea Holdings (FTRE) Restructuring Costs (2022 - 2026) Analysis & Trends

Fortrea Holdings (FTRE) has 2 years of Restructuring Costs data on file, last reported at $7.6 million in Q4 2023.

  • Quarterly Restructuring Costs rose 181.48% year-over-year to $7.6 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $25.8 million (changed N/A YoY) and the FY2023 annual result came in at $24.3 million, down 20.33% from the prior year.
  • Restructuring Costs retreated to $7.6 million in Q4 2023, from $11.6 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $13.0 million in Q2 2022 to a low of $2.7 million in Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 140.22 Bn 132.37 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 86.04 Bn 78.05 Bn 3.93 Bn
3 Argenx Se 63.70 Bn 58.52 Bn 1.37 Bn
4 Moderna 57.56 Bn 52.42 Bn 52.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn -
6 BeOne Medicines 40.16 Bn 35.06 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.63 Bn 32.32 Bn 992.69 Mn
8 Royalty Pharma 28.63 Bn 27.79 Bn -
9 Insmed 27.73 Bn 26.57 Bn 358.27 Mn
10 Fortrea Holdings 1.73 Bn 1.56 Bn 139.20 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.70 Mn
Mar 31, 2026 6.70 Mn
Dec 31, 2025 22.40 Mn
Sep 30, 2025 4.90 Mn
Jun 30, 2025 10.30 Mn
Mar 31, 2025 6.50 Mn
Dec 31, 2024 27.60 Mn
Sep 30, 2024 8.80 Mn
Jun 30, 2024 10.40 Mn
Mar 31, 2024 3.30 Mn
Dec 31, 2023 6.90 Mn
Sep 30, 2023 10.10 Mn
Jun 30, 2023 3.60 Mn
Mar 31, 2023 600,000.00
Dec 31, 2022 -1.90 Mn
Sep 30, 2022 5.20 Mn
Jun 30, 2022 13.00 Mn